• Investment World
• eWorld
• Brand Line
• Mentor
• Life
• Brand Quest
• The New Manager

Stocks

• Quotes
• SE Diary
• Scoreboard
• Open-End Mutual Fund

Cross Currency

• Rates
  
  

Shipping

• Ports
  
  

Archives

• Yesterday
• Datewise
• Resources
• In Focus
• In Depth
• Events 2007

Group Sites

• The Hindu
• The Hindu ePaper
• Business Line
• Business Line ePaper
• Sportstar
• Frontline
• The Hindu eBooks
• The Hindu Images

Hyderabad, March 24

Suven Life Sciences Ltd has been granted two product patents in Eurasia for its New Chemical Entities (NCEs) for the treatment of disorders associated with neurodegenerative diseases. The patents (nos. 009193 and 009367) are valid till 2023 in all contracting countries such as Armenia, Azerbaijan, Belarus, Kyrgyzstan, Kazakhstan, Moldova, Russia, Tajikistan and Turkmenistan. “We are very pleased by the grant of these patents to Suven for our drug candidates that are being developed for CNS disorders, which target an $18 billion potential market opportunity globally,” Mr Venkat Jasti, Chief Executive Officer of Hyderabad-based Suven Life Sciences, said in a release. Products out of these inventions, which were in pre-clinical development, may be out-licensed at the stage of clinical phase-I or phase-II stage. The granted claims of the patents include the class of selective 5-HT compounds discovered by Suven and are being developed as therapeutic agents. They would be useful in the treatment of cognitive impairment associated with neurodegenerative disorders such as attention deficient hyperactivity, Alzheimer’s, Parkinson’s, schizophrenia and Huntington’s, the release added.

– Our Bureau

More Stories on : IPR | Pharmaceuticals

Article E-Mail :: Comment :: Syndication :: Printer Friendly Page

Stories in this Section
Avesthagen begins bio-actives trials

Copyright © 2008, The Hindu Business Line. Republication or redissemination of the contents of this screen are expressly prohibited without the written consent of The Hindu Business Line